tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MannKind price target raised to $8 from $7 at RBC Capital

RBC Capital analyst Douglas Miehm raised the firm’s price target on MannKind (MNKD) to $8 from $7 and keeps an Outperform rating on the shares. The firm views the company’s announced acquisition of scPharmaceuticals (SCPH) positively as it adds a high-growth commercial asset with a large total addressable market of about $13B, diversifies MannKind revenue base, and the acquisition multiple is “attractive”, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1